PURPOSE: To describe outcomes after unrelated donor stem cell transplantation (HCT) in children (< 18 months at diagnosis) with acute leukemia and compare these with outcomes after human leukocyte antigen (HLA)-matched sibling donor HCT. PATIENTS AND METHODS: We compared the results of unrelated donor HCT with bone marrow (n = 85) or cord blood grafts (n = 81) and HLA-matched sibling donor HCT with bone marrow grafts (n = 101) for acute myeloid or acute lymphoblastic leukemia using Cox proportional hazards models. Unrelated donor HCT recipients were younger, more likely to have MLL gene rearrangement, to have advanced leukemia, and to receive irradiation before HCT. RESULTS: Treatment-related mortality rates were 6%, 15%, and 31% after matched sibling, unrelated donor bone marrow, and cord blood HCT, respectively. Risks of relapse, overall and leukemia-free survival were significantly associated with disease status at transplantation. Though leukemia recurrence was lowest after unrelated donor HCT in first clinical remission (CR), overall survival, and leukemia-free survival rates were similar after matched sibling and unrelated donor HCT, after adjustment for disease status. Relapse, overall and leukemia-free survival did not differ by graft type (bone marrow v cord blood) or type of leukemia. Three-year probabilities of leukemia-free survival were 49% and 54% after HLA-matched sibling and unrelated donor transplantation in first CR, respectively. Corresponding rates for those with advanced leukemia were 20% and 30%. CONCLUSION: Unrelated donor HCT should be considered for infants with acute leukemia in first CR using the same eligibility criteria as are currently used for those with HLA matched sibling donors.
PURPOSE: To describe outcomes after unrelated donor stem cell transplantation (HCT) in children (< 18 months at diagnosis) with acute leukemia and compare these with outcomes after human leukocyte antigen (HLA)-matched sibling donor HCT. PATIENTS AND METHODS: We compared the results of unrelated donor HCT with bone marrow (n = 85) or cord blood grafts (n = 81) and HLA-matched sibling donor HCT with bone marrow grafts (n = 101) for acute myeloid or acute lymphoblastic leukemia using Cox proportional hazards models. Unrelated donor HCT recipients were younger, more likely to have MLL gene rearrangement, to have advanced leukemia, and to receive irradiation before HCT. RESULTS: Treatment-related mortality rates were 6%, 15%, and 31% after matched sibling, unrelated donor bone marrow, and cord blood HCT, respectively. Risks of relapse, overall and leukemia-free survival were significantly associated with disease status at transplantation. Though leukemia recurrence was lowest after unrelated donor HCT in first clinical remission (CR), overall survival, and leukemia-free survival rates were similar after matched sibling and unrelated donor HCT, after adjustment for disease status. Relapse, overall and leukemia-free survival did not differ by graft type (bone marrow v cord blood) or type of leukemia. Three-year probabilities of leukemia-free survival were 49% and 54% after HLA-matched sibling and unrelated donor transplantation in first CR, respectively. Corresponding rates for those with advanced leukemia were 20% and 30%. CONCLUSION: Unrelated donor HCT should be considered for infants with acute leukemia in first CR using the same eligibility criteria as are currently used for those with HLA matched sibling donors.
Authors: Vincent T Ho; Haesook T Kim; Julie Aldridge; Deborah Liney; Grace Kao; Philippe Armand; John Koreth; Corey Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Edwin P Alyea Journal: Biol Blood Marrow Transplant Date: 2010-12-27 Impact factor: 5.742
Authors: A A Hamidieh; M Ostadali Dehaghi; P Paragomi; S Navaei; A Jalali; G Ghazizadeh Eslami; M Behfar; A Ghavamzadeh Journal: Bone Marrow Transplant Date: 2015-01-26 Impact factor: 5.483
Authors: Peter J Shaw; Fangyu Kan; Kwang Woo Ahn; Stephen R Spellman; Mahmoud Aljurf; Mouhab Ayas; Michael Burke; Mitchell S Cairo; Allen R Chen; Stella M Davies; Haydar Frangoul; James Gajewski; Robert Peter Gale; Kamar Godder; Gregory A Hale; Martin B A Heemskerk; John Horan; Naynesh Kamani; Kimberly A Kasow; Ka Wah Chan; Stephanie J Lee; Wing H Leung; Victor A Lewis; David Miklos; Machteld Oudshoorn; Effie W Petersdorf; Olle Ringdén; Jean Sanders; Kirk R Schultz; Adriana Seber; Michelle Setterholm; Donna A Wall; Lolie Yu; Michael A Pulsipher Journal: Blood Date: 2010-07-29 Impact factor: 22.113
Authors: F Locatelli; R Masetti; R Rondelli; M Zecca; F Fagioli; A Rovelli; C Messina; E Lanino; A Bertaina; C Favre; G Giorgiani; M Ripaldi; O Ziino; G Palumbo; M Pillon; A Pession; S Rutella; A Prete Journal: Bone Marrow Transplant Date: 2014-11-10 Impact factor: 5.483
Authors: Navneet S Majhail; Pintip Chitphakdithai; Brent Logan; Roberta King; Steven Devine; Susan N Rossmann; Gregory Hale; Robert J Hartzman; Chatchada Karanes; Ginna G Laport; Eneida Nemecek; Edward L Snyder; Galen E Switzer; John Miller; Willis Navarro; Dennis L Confer; John E Levine Journal: Biol Blood Marrow Transplant Date: 2014-10-15 Impact factor: 5.742
Authors: Mark B Geyer; Judith S Jacobson; Jason Freedman; Diane George; Virginia Moore; Carmella van de Ven; Prakash Satwani; Monica Bhatia; James H Garvin; Mary Brigid Bradley; Lauren Harrison; Erin Morris; Phyllis Della-Latta; Joseph Schwartz; Lee A Baxter-Lowe; Mitchell S Cairo Journal: Br J Haematol Date: 2011-08-16 Impact factor: 6.998
Authors: Sergio A Giralt; Charles F LeMaistre; Navneet S Majhail; Stephanie H Farnia; Paul A Carpenter; Richard E Champlin; Stephen Crawford; David I Marks; James L Omel; Paul J Orchard; Jeanne Palmer; Wael Saber; Bipin N Savani; Paul A Veys; Christopher N Bredeson Journal: Biol Blood Marrow Transplant Date: 2015-08-07 Impact factor: 5.742